Savolitinib

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca.[1] It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.[2]

Savolitinib

Clinical data
Other names	Volitinib
Identifiers
IUPAC name 3-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine
CAS Number	1313725-88-0
ChemSpider	34501055
UNII	2A2DA6857R
KEGG	D11139
ECHA InfoCard	100.238.920
Chemical and physical data
Formula	C17H15N9
Molar mass	345.370 g·mol^−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](C1=CN2C=CN=C2C=C1)N3C4=NC(=CN=C4N=N3)C5=CN(N=C5)C
InChI InChI=1S/C17H15N9/c1-11(12-3-4-15-18-5-6-25(15)10-12)26-17-16(22-23-26)19-8-14(21-17)13-7-20-24(2)9-13/h3-11H,1-2H3/t11-/m0/s1 Key:XYDNMOZJKOGZLS-NSHDSACASA-N

References

1. https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fsavolitinib.pdf
2. adisinsight.springer.com/drugs/800035893